

Dostarlimab with platinum-based chemotherapy for treating primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency

Information for the public

Published: 22 May 2025

www.nice.org.uk

Dostarlimab (Jemperli) with platinum-based chemotherapy is available on the NHS. It is a possible treatment for when systemic treatment is suitable in adults with primary endometrial cancer that has spread (advanced) or come back (recurrent) and has high microsatellite instability or mismatch repair deficiency.

Systemic treatment is a treatment that works throughout the whole body.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. See [our webpage on making decisions about your care](#).

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

Information and support

The [NHS webpage on endometrial \(womb\) cancer](#) may be a good place to find out more.

These organisations can give you advice and support:

- [Peaches Womb Cancer Trust](#), admin@peachestrust.org
- [Cancer Research UK](#), 0808 800 4040
- [Macmillan Cancer Support](#), 0808 808 0000

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-7018-6